Organization and Significant Accounting Policies - Concentration Risk (Details) - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue | Nacalai USA, Inc.
Product Information [Line Items]
Concentration risk	19.30%
Revenue | CureVac N.V.
Product Information [Line Items]
Concentration risk			15.30%
Revenue | BioNTech SE
Product Information [Line Items]
Concentration risk		34.80%	29.50%
Revenue | Pfizer Inc.
Product Information [Line Items]
Concentration risk		26.40%	23.30%
Accounts Receivable, net | Nacalai USA, Inc.
Product Information [Line Items]
Concentration risk	27.30%	20.30%
Accounts Receivable, net | CureVac N.V.
Product Information [Line Items]
Concentration risk	13.00%	15.70%
Accounts Receivable, net | BioNTech SE
Product Information [Line Items]
Concentration risk		12.00%
Accounts Receivable, net | Pfizer Inc.
Product Information [Line Items]
Concentration risk		19.20%